Endothelial glycocalyx shedding during active COVID-19 infection and its effect on disease severity

References

• Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395(10223):497–506. DOI:10.1016/S0140-6736(20)30183-5
   PubMed Web of Science ®Google Scholar
• Auld SC, Caridi-Scheible M, Blum JM, et al. ICU and ventilator mortality among critically ill adults with coronavirus disease 2019. Crit Care Med. 2020;48(9):e799–804. DOI:10.1097/CCM.0000000000004457
   PubMed Web of Science ®Google Scholar
• Cui S, Chen S, Li X, et al. Prevalence of venous thromboembolism in patients with severe novel coronavirus pneumonia. J Thromb Haemost. 2020;18(6):1421–1424. DOI:10.1111/jth.14830
   PubMed Web of Science ®Google Scholar
• Klok FA, Kruip M, van der Meer NJM, et al. Incidence of thrombotic complications in critically ill ICU patients with COVID-19. Thromb Res. 2020;191:145–147.
   PubMed Web of Science ®Google Scholar
• Henry BM, Vikse J, Benoit S, et al. Hyperinflammation and derangement of renin-angiotensin-aldosterone system in COVID-19: a novel hypothesis for clinically suspected hypercoagulopathy and microvascular immunothrombosis. Clin Chim Acta. 2020;507:167–173.
   PubMed Web of Science ®Google Scholar
• Ackermann M, Verleden SE, Kuehnel M, et al. Pulmonary vascular endothelialitis, thrombosis, and angiogenesis in covid-19. N Engl J Med. 2020;383(2):120–128. DOI:10.1056/NEJMoa2015432
   PubMed Web of Science ®Google Scholar
• Dogné S, Flamion B. Endothelial glycocalyx impairment in disease: focus on hyaluronan shedding. Am J Pathol. 2020;190(4):768–780.
   PubMed Web of Science ®Google Scholar
• Uchimido R, Schmidt EP, Shapiro NI. The glycocalyx: a novel diagnostic and therapeutic target in sepsis. crit care. 2019;23(1):16.
   PubMed Web of Science ®Google Scholar
• Fraser DD, Patterson EK, Slessarev M, et al. Endothelial injury and glycocalyx degradation in critically ill coronavirus disease 2019 patients: implications for microvascular platelet aggregation. Crit Care Explor. 2020;2(9):e0194. DOI:10.1097/CCE.0000000000000194
   PubMedGoogle Scholar
• Mellhammar L, Thelaus L, Elén S, et al. Heparin Binding Protein and Endothelial Glycocalyx Markers in Severe COVID-19 – a Prospective Observational Cohort Study. 2020.
   Google Scholar
• IBM Corp. IBM SPSS Statistics for Windows, Version 20.0. Armonk, NY: IBM Corp; 2012.
   Google Scholar
• Li H, Liu SM, Yu XH, et al. Coronavirus disease 2019 (COVID-19): current status and future perspectives. Int J Antimicrob Agents. 2020;55(5):105951. DOI:10.1016/j.ijantimicag.2020.105951
   PubMed Web of Science ®Google Scholar
• Hutchings SD, Watchorn J, Trovato F, et al. Microcirculatory, endothelial, and inflammatory responses in critically ill patients with COVID-19 are distinct from those seen in septic shock: a case control study. Shock. 2021;55(6):752–758. DOI:10.1097/SHK.0000000000001672
   PubMed Web of Science ®Google Scholar
• Butler PJ, Bhatnagar A, Tarbell J. Mechanobiology of the abluminal glycocalyx. Biorheology. 2019;56(2–3):101–112.
   PubMed Web of Science ®Google Scholar
• Okada H, Yoshida S, Hara A, et al. Vascular endothelial injury exacerbates coronavirus disease 2019: the role of endothelial glycocalyx protection. Microcirculation. 2021;28(3):e12654. DOI:10.1111/micc.12654
   PubMed Web of Science ®Google Scholar
• Varga Z, Flammer AJ, Steiger P, et al. Endothelial cell infection and endotheliitis in COVID-19. Lancet. 2020;395(10234):1417–1418. DOI:10.1016/S0140-6736(20)30937-5
   PubMed Web of Science ®Google Scholar
• Fara A, Mitrev Z, Rosalia RA, et al. Cytokine storm and COVID-19: a chronicle of pro-inflammatory cytokines. Open Biol. 2020;10(9):200160. DOI:10.1098/rsob.200160
   PubMed Web of Science ®Google Scholar
• Dhar SK, Vishnupriyan K, Damodar S, et al. IL-6 and IL-10 as predictors of disease severity in COVID-19 patients: results from meta-analysis and regression. Heliyon. 2021;7(2):e06155. DOI:10.1016/j.heliyon.2021.e06155
   PubMed Web of Science ®Google Scholar
• Nasonov E, Samsonov M. The role of Interleukin 6 inhibitors in therapy of severe COVID-19. Biomed Pharmacother. 2020;131:110698.
   PubMed Web of Science ®Google Scholar
• Cavalli G, Larcher A, Tomelleri A, et al. Interleukin-1 and interleukin-6 inhibition compared with standard management in patients with COVID-19 and hyperinflammation: a cohort study. Lancet Rheumatol. 2021;3(4):e253–261. DOI:10.1016/S2665-9913(21)00012-6
   PubMedGoogle Scholar
• Zhang J, Hao Y, Ou W, et al. Serum interleukin-6 is an indicator for severity in 901 patients with SARS-CoV-2 infection: a cohort study. J Transl Med. 2020;18(1):406. DOI:10.1186/s12967-020-02571-x
   PubMed Web of Science ®Google Scholar
• Guirao JJ, Cabrera CM, Jiménez N, et al. High serum IL-6 values increase the risk of mortality and the severity of pneumonia in patients diagnosed with COVID-19. Mol Immunol. 2020;128:64–68.
   PubMed Web of Science ®Google Scholar
• Sun H, Guo P, Zhang L, et al. Serum interleukin-6 concentrations and the severity of COVID-19 Pneumonia: a retrospective study at a single center in Bengbu City, Anhui Province, China, in January and February 2020. Med Sci Monit. 2020;26:e926941.
   PubMed Web of Science ®Google Scholar
• Lippi G, Favaloro EJ. D-dimer is Associated with severity of coronavirus disease 2019: a pooled analysis. Thromb Haemost. 2020;120(5):876–878.
   PubMed Web of Science ®Google Scholar
• Bilaloglu S, Aphinyanaphongs Y, Jones S, et al. Thrombosis in Hospitalized patients with COVID-19 in a New York City health system. JAMA. 2020;324(8):799–801. DOI:10.1001/jama.2020.13372
   PubMed Web of Science ®Google Scholar
• Ahnach M, Zbiri S, Nejjari S, et al. C-reactive protein as an early predictor of COVID-19 severity. J Med Biochem. 2020;39(4):500–507. DOI:10.5937/jomb0-27554
   PubMed Web of Science ®Google Scholar
• Luo X, Zhou W, Yan X, et al. Prognostic value of C-Reactive Protein in Patients with Coronavirus 2019. Clin Infect Dis. 2020;71(16):2174–2179. DOI:10.1093/cid/ciaa641
   PubMed Web of Science ®Google Scholar
• Wang L. C-reactive protein levels in the early stage of COVID-19. Med Mal Infect. 2020;50(4):332–334.
   PubMed Web of Science ®Google Scholar
• Szolnoky G. Sulodexide may be a real alternative to low molecular weight heparins in the prevention of covid‐19 induced vascular complications. Dermatologic Therapy. 2020;33(6). DOI:10.1111/dth.14437
   Web of Science ®Google Scholar
• Sagris M, Theofilis P, Antonopoulos AS, et al. Genetic predisposition and Inflammatory Inhibitors in COVID-19: where do we stand? Biomedicines. 2022;10(2):242.
   PubMed Web of Science ®Google Scholar